Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Endo International plc

$ENDP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ENDP alert in real time by email
SC 13G 1 ie00bj3v9050_090722.txt ie00bj3v9050_090722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ENDO INTERNATIONAL PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BJ3V905 -------------------------------------------------------- (SEDOL Number) August 31, 2022 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BJ3V905 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 1436502 (6) Shared voting power 0 (7) Sole dispositive power 1556382 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 1556382 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 0.7% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- ENDO INTERNATIONAL PLC Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- Minerva House, Simmonscourt Road, Ballsbridge DUBLIN 4 Ireland Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 55 East 52nd Street New York, NY 10055 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) SEDOL No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 1556382 Percent of class 0.7% Number of shares as to which such person has: Sole power to vote or to direct the vote 1436502 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 1556382 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person [ N/A ] Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 7, 2022 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary Aperio Group, LLC BlackRock Advisors, LLC BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BLACKROCK, INC., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Christopher Meade, Daniel Waltcher, Una Neary, Richard Cundiff, Charles Park, Enda McMahon, Arlene Klein, Con Tzatzakis, Karen Clark, David Maryles, Daniel Ronnen, John Stelley, Daniel Riemer, Elizabeth Kogut, Maureen Gleeson, Daniel Kalish and Spencer Fleming acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, is acting certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, Including without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any amendments to any of the Foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 8th day of December, 2015 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 2nd day of January, 2019. BLACKROCK, INC. By:_ /s/ Daniel Waltcher Name: Daniel Waltcher Title: Deputy General Counsel
Get the next $ENDP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENDP

DatePrice TargetRatingAnalyst
5/6/2022$3.00 → $1.00Neutral → Underweight
Piper Sandler
3/9/2022$11.00 → $6.00Buy
Citigroup
3/2/2022$5.00 → $3.00Neutral
Piper Sandler
3/2/2022$5.00 → $2.00Equal-Weight → Underweight
Barclays
12/16/2021$7.00 → $5.00Equal-Weight
Barclays
8/31/2021$10.00 → $3.00Overweight → Neutral
Piper Sandler
8/9/2021$6.00 → $5.00Sector Perform
RBC Capital
More analyst ratings

$ENDP
 Press Releases

Fastest customizable press release news feed in the world

See more

  • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

    MONTREAL, June 12, 2023 /CNW/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sensitivit

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

    MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sen

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

    Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebted

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ENDP
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENDP
 SEC Filings

See more

$ENDP
 Leadership Updates

Live Leadership Updates

See more

  • Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

    DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022.  He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. "Dr. Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. "His broad therapeutic expertis

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Endo Appoints Jennifer M. Chao to Board of Directors

    DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately.  Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board.  Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Continue Reading Jennifer M. Chao Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy.  She is the founder

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • POINT Biopharma Announces New Board Appointments

    Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Kn

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
 Financials

Live finance-specific insights

See more

  • ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

    DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer. "As we manage thro

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

    DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durabl

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Endo to Announce First-Quarter 2022 Financial Results

    DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from May 6, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on May

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more